| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |